Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder

References

• APADiagnostic and Statistical Manual of Mental Disorders4th edWashington, DCAmerican Psychiatric Association1994
   Google Scholar
• VolkmarFRMcPartlandJCFrom Kanner to DSM-5: autism as an evolving diagnostic conceptAnnu Rev Clin Psychol Epub1292013
   Web of Science ®Google Scholar
• KulageKMSmaldoneAMCohnEGHow will DSM-5 affect autism diagnosis? A systematic literature review and meta-analysisJ Autism Dev Disord Epub2162014
   Web of Science ®Google Scholar
• Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal InvestigatorsPrevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010MWR Surveill Sum20142863Suppl 2121
   Google Scholar
• Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal InvestigatorsCenters for Disease Control and PreventionPrevalence of autism spectrum disorders – autism and developmental disabilities monitoring network, 14 sites, United States, 2002MMWR Surveill Summ200756122817287715
   PubMedGoogle Scholar
• SchaeferGBMendelsohnNJProfessional Practice and Guidelines CommitteeClinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisionsGenet Med201315539940723519317
   PubMed Web of Science ®Google Scholar
• RossignolDAGenuisSJFryeREEnvironmental toxicants and autism spectrum disorders: a systematic reviewTransl Psychiatry20144e36024518398
   PubMed Web of Science ®Google Scholar
• HallmayerJClevelandSTorresAGenetic heritability and shared environmental factors among twin pairs with autismArch Gen Psychiatry201168111095110221727249
   PubMed Web of Science ®Google Scholar
• RossignolDAFryeREA review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposuresMol Psychiatry201217438940122143005
   PubMed Web of Science ®Google Scholar
• CoghlanSHorderJInksterBMendezMAMurphyDGNuttDJGABA system dysfunction in autism and related disorders: from synapse to symptomsNeurosci Biobehav Rev20123692044205522841562
   PubMed Web of Science ®Google Scholar
• ChadmanKKGuarigliaSRYooJHNew directions in the treatment of autism spectrum disorders from animal model researchExpert Opin Drug Discov20127540741622494457
   PubMed Web of Science ®Google Scholar
• StafstromCEHagermanPJPessahINPathophysiology of Epilepsy in Autism Spectrum DisordersNoebelsJLAvoliMRogawskiMAOlsenRWDelgado-EscuetaAVJasper’s Basic Mechanisms of the Epilepsies4th edBethesda, MDNational Center for Biotechnology Information2012
   Google Scholar
• TranfagliaMRThe psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndromeDev Neurosci201133533734821893938
   PubMed Web of Science ®Google Scholar
• CliffordSDissanayakeCBuiQMHugginsRTaylorAKLoeschDZAutism spectrum phenotype in males and females with fragile X full mutation and premutationJ Autism Dev Disord20073747384717031449
   PubMed Web of Science ®Google Scholar
• OsterweilEKKruegerDDReinholdKBearMFHypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndromeJ Neurosci20103046156161562721084617
   PubMed Web of Science ®Google Scholar
• YanQJRammalMTranfagliaMBauchwitzRPSuppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEPNeuropharmacology20054971053106616054174
   PubMed Web of Science ®Google Scholar
• DolenGOsterweilERaoBSCorrection of fragile X syndrome in miceNeuron200756695596218093519
   PubMed Web of Science ®Google Scholar
• CarlsonGCGlutamate receptor dysfunction and drug targets across models of autism spectrum disordersPharmacol Biochem Behav2012100485085421315104
   PubMed Web of Science ®Google Scholar
• BraatSKooyRFFragile X syndrome neurobiology translates into rational therapyDrug Discov Today Epub272014
   Web of Science ®Google Scholar
• Sanchez-PonceRWangLQLuWvon HehnJCherubiniMRushRMetabolic and pharmacokinetic differentiation of STX209 and racemic baclofen in humansMetabolites20122596613
   PubMedGoogle Scholar
• LalRSukbuntherngJTaiEHArbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofenJ Pharmacol Exp Ther2009330391192119502531
   PubMed Web of Science ®Google Scholar
• VakilNBHuffFJBianAJonesDSStamlerDArbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled studyAm J Gastroenterol201110681427143821519360
   PubMed Web of Science ®Google Scholar
• GersonLBHuffFJHilaAArbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux diseaseAm J Gastroenterol201010561266127520040914
   PubMed Web of Science ®Google Scholar
• VakilNBHuffFJCundyKCRandomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease – insights into study design for transient lower sphincter relaxation inhibitorsAliment Pharmacol Ther201338210711723721547
   PubMed Web of Science ®Google Scholar
• NancePWHuffFJMartinez-ArizalaAEfficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injurySpinal Cord20114999749021577221
   PubMed Web of Science ®Google Scholar
• HowickJChalmersIGlasziouPThe Oxford 2011 Levels of Evidence: Oxford Centre for Evidence-Based Medicine2011 [cited September 3, 2011]. Available from: http://www.cebm.net/index.aspx?o=5653Accessed March 21, 2014
   Google Scholar
• HendersonCWijetungeLKinoshitaMNReversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofenSci Transl Med20124152152ra28
   Web of Science ®Google Scholar
• PaceyLKTharmalingamSHampsonDRSubchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndromeJ Pharmacol Exp Ther2011338389790521636656
   PubMed Web of Science ®Google Scholar
• Berry-KravisEMHesslDRathmellBEffects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trialSci Transl Med20124152152ra27
   Web of Science ®Google Scholar
• EricksonCAVeenstra-VanderweeleJMMelmedRDSTX209 (Arbaclofen) for autism spectrum disorders: an 8-week open-label studyJ Autism Dev Disord201344495896424272415
   PubMed Web of Science ®Google Scholar
• DelahuntyCWalton-BowenKKuriyamaNRandomized, Controlled, Phase 2 Trial of STX209 (Arbaclofen) for Social Function in ASDOrlando, FLAmerican Acadamy of Pediatrics2013
   Google Scholar